ArticleCancer medicine2023

HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma.

Xianglai Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.